Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4 ‐Year Follow‐Up and Analysis of Relative Progression‐Free Survival From the Randomized ELOQUENT‐2 Trial

Cancer, EarlyView.

Source: Cancer - September 11, 2018 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, MD , Sagar Lonial, MD , Keith A. Betts, PhD , Clara Chen, PhD , Miriam L. Zichlin, MPH , Alexander Brun, PharmD , James E. Signorovitch, PhD , Dinara Makenbaeva, MD , Sabeen Mekan, MD , Oumar Sy, PhD , Katja We Source Type: research